
Stryker Corporation company profile
$309.64−0.88%Close 13 Nov 2026
About Stryker Corporation
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. The company's products are used for medical surgery and neurotechnology (60% of 2024 revenues), which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery (40% of 2024 revenues), which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.
The company is ranked 195th on the Fortune 500 and 331st on the Forbes Global 2000.
From Wikipedia, shared under CC BY-SA.
Company facts
| Ticker | SYK · NYSE |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 310764 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Ronda E. Stryker | Director | 15.4M · 4% | Open-market sale, 6 Nov 2026 |
|---|
| Kevin A. Lobo | Chair and CEO · Director | 1.2M · < 1% | Shares withheld for tax, 21 Mar 2026 |
|---|
| J. Andrew Pierce | Group President | 246K · < 1% | Shares withheld for tax, 21 Mar 2026 |
|---|
| Spencer S. Stiles | President and COO | 243K · < 1% | Gift, 1 Jun 2026 |
|---|
| Glenn S. Boehnlein | VP, Chief Financial Officer | 196K · < 1% | Option exercise, 21 Mar 2025 |
|---|
| Viju S. Menon | Group President | 178K · < 1% | Shares withheld for tax, 21 Mar 2026 |
|---|
| Preston W. Wells | VP, Chief Financial Officer | 29.1K · < 1% | Code J, 24 Sep 2026 |
|---|
| Andrew K. Silvernail | Director | 21.3K · < 1% | Grant or award, 6 May 2026 |
|---|
| Mary K. Brainerd | Director | 9.5K · < 1% | Grant or award, 6 May 2026 |
|---|
| Rajeev Suri | Director | 5.9K · < 1% | Grant or award, 6 May 2026 |
|---|
| Lisa M. Skeete Tatum | Director | 3.9K · < 1% | Grant or award, 6 May 2026 |
|---|
| Sherilyn S. McCoy | Director | 3.8K · < 1% | Grant or award, 6 May 2026 |
|---|
| Giovanni Caforio, M.D. | Director | 3.2K · < 1% | Grant or award, 6 May 2026 |
|---|
| Rachel M. Ruggeri | Director | 679 · < 1% | Grant or award, 6 May 2026 |
|---|
| Crotty Dylan Bram | Group President | — | Open-market sale, 21 Aug 2026 |
|---|
| King Debra | See Remarks | — | Open-market sale, 18 Aug 2026 |
|---|
| Montagnino Kimberly Ann | VP, Chief Comm. Officer | — | Shares withheld for tax, 1 Aug 2026 |
|---|
| Fletcher Robert S | VP, Chief Legal Officer | — | Shares withheld for tax, 1 Aug 2026 |
|---|
| Fink M Kathryn | VP, Chief HR Officer | — | Shares withheld for tax, 1 Aug 2026 |
|---|
| Emmanuel P. Maceda | Director | — | Grant or award, 6 May 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
SYK in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.